Revenue and net income rose sharply year-over-year, driven by strong Bio-Chemical sales and improved margins. Major investments in new production capacity and ongoing clinical trials support future growth, while risk management focuses on FX and credit exposures.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.